This week, Amgen announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label variation for its reference pegfilgrastim to now include the branded Neulasta Onpro Kit.
This week, Amgen announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label variation for its reference pegfilgrastim to now include the branded Neulasta Onpro Kit. Following the CHMP positive opinion, the centralized European marketing authorization of reference pegfilgrastim will be updated to include the delivery system of the device in its label.
The Onpro Kit device uses pegfilgrastim in an on-body injector that allows a patient to forego a visit to the physician’s office to receive an injection of the drug.
“The Neulasta Onpro Kit is a showpiece of our patient-centric approach and continued investment in advancing the field of G-CSF administration,” said David M. Reese, MD, senior vice president of translational sciences and oncology at Amgen, in a statement.
The Onpro Kit has been approved in the United States since August 2015, and can be very costly. The eventual introduction of pegfilgrastim biosimilars into the marketplace could provide competition to the reference product due to lower prices, but the convenience provided by the on-body device could help Amgen to retain its market share for the reference drug.
Meanwhile, Gedeon Richter, a German-based pharmaceutical company, announced today that the EMA has accepted its resubmission of a marketing authorization application (MAA) for a proposed pegfilgrastim biosimilar.
In December 2016, following a meeting with the CHMP, Gedeon Richter withdrew its MAA due to committee concerns that the data provided did not allow for a positive benefit-risk assessment.
Gedeon Richter made the decision to resubmit its application to the EMA after completion of an additional clinical study that provided data demonstrating similarity of both the pharmacokinetics and pharmacodynamics of the proposed biosimilar and reference Neulasta.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.